HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Pharming (NASDAQ:PHAR) and maintains a $37 price target.
March 14, 2024 | 4:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pharming Group has been reiterated with a Buy rating and a $37 price target by HC Wainwright & Co. analyst Joseph Pantginis.
The reiteration of a Buy rating and maintenance of a $37 price target by a reputable analyst could lead to increased investor confidence in Pharming Group, potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100